Movatterモバイル変換

[0]ホーム
URL:

Skip to main content
Springer Nature Link
Log in

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To determine the inhibitory potency of letrozole and its main human metabolite, 4,4′-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes.

Methods

Letrozole and its metabolite were incubated with human liver microsomes (HLMs) (or expressed CYP isoforms) and NADPH in the absence (control) and presence of the test inhibitor.

Results

Letrozole was a potent competitive inhibitor of CYP2A6 (Ki 4.6 ± 0.05 μM and 5.0 ± 2.4 μM in HLMs and CYP2A6, respectively) and a weak inhibitor of CYP2C19 (Ki 42.2 μM in HLMs and 33.3 μM in CYP2C19), while its metabolite showed moderate inhibition of CYP2C19 and CYP2B6. Letrozole or its metabolite had negligible effect on other CYPs.

Conclusions

Based on the in vitroKi values, letrozole is predicted to be a weak inhibitor of CYP2A6 in vivo. Letrozole and its major human metabolite show inhibitory activity towards other CYPs, but clinically relevant drug interactions seem less likely as theKi values are above the therapeutic plasma concentrations of letrozole.

This is a preview of subscription content,log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
¥17,985 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Japan)

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

CYPs:

Cytochrome P450s

HLMs:

Human liver microsomes

HPLC:

High-performance liquid chromatography

References

  1. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270–282

    Article PubMed CAS  Google Scholar 

  2. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618

    Article PubMed CAS  Google Scholar 

  3. Buzdar AU, Robertson JF (2006) Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother 40:1572–1583

    Article PubMed CAS  Google Scholar 

  4. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431–2442

    Article PubMed CAS  Google Scholar 

  5. Ryan KJ (1959) Biological aromatization of steroids. J Biol Chem 234:268–272

    PubMed CAS  Google Scholar 

  6. Scott LJ, Keam SJ (2006) Letrozole: in postmenopausal hormone-responsive early-stage breast cancer. Drugs 66:353–362

    Article PubMed CAS  Google Scholar 

  7. Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757

    Article PubMed  Google Scholar 

  8. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092

    Article PubMed CAS  Google Scholar 

  9. Buzdar AU, Coombes RC, Goss PE, Winer EP (2008) Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112:700–709

    Article PubMed CAS  Google Scholar 

  10. Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39

    Article PubMed CAS  Google Scholar 

  11. Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61–74

    Article PubMed CAS  Google Scholar 

  12. Bhatnagar AS (2007) The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 105(Suppl 1):7–17

    Article PubMed CAS  Google Scholar 

  13. Wrz B, Valles B, Parkinson A, Madan A, Probst A, Zimmerlin A, Gut J (1996) CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole. ISSX Proc 10:359 (Abstract)

    Google Scholar 

  14. Grimm SW, Dyroff MC (1997) Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 25:598–602

    PubMed CAS  Google Scholar 

  15. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111–180

    Article PubMed CAS  Google Scholar 

  16. Desta Z, Ward BA, Flockhart DA (2005) In vitro letrozoleN-dealkylation is mainly catalyzed by human cytochrome P450 (CYP) 3A. Clin Pharmacol Ther 77:79 (Abstract)

    Article  Google Scholar 

  17. Product information. Novartis Pharmaceutical Canada Inc. Prescribing information femara1 (letrozole).http://www.pharma.ca.novartis.com/downloads/e/femara_scrip_e.pdf (online 23 April 2007)

  18. Pfister CU, Martoni A, Zamagni C et al (2001) Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 22:191–197

    Article PubMed CAS  Google Scholar 

  19. Tao X, Piao H, Canney DJ, Borenstein MR, Nnane IP (2007) Biotransformation of letrozole in rat liver microsomes: effects of gender and tamoxifen. J Pharm Biomed Anal 43:1078–1085

    Article PubMed CAS  Google Scholar 

  20. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254

    Article PubMed CAS  Google Scholar 

  21. Jeong S, Nguyen PD, Desta Z (2009) Comprehensive in vitro inhibition analysis of 8 cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A. Antimicrob Agents Chemother 53:541–551

    Article PubMed CAS  Google Scholar 

  22. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853–862

    PubMed CAS  Google Scholar 

  23. Greenlee WF, Poland A (1978) An improved assay of 7-ethoxycoumarinO-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. J Pharmacol Exp Ther 205:596–605

    PubMed CAS  Google Scholar 

  24. Pearce R, Greenway D, Parkinson A (1992) Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 298:211–225

    Article PubMed CAS  Google Scholar 

  25. Draper AJ, Madan A, Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47–61

    Article PubMed CAS  Google Scholar 

  26. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300

    Article PubMed CAS  Google Scholar 

  27. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM (2002) Amodiaquine clearance and its metabolism toN-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399–407

    Article PubMed CAS  Google Scholar 

  28. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL (2007) Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 82:197–203

    Article PubMed CAS  Google Scholar 

  29. Wang YH, Jones DR, Hall SD (2005) Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664–671

    Article PubMed CAS  Google Scholar 

  30. Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA (1998) Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 285:428–437

    PubMed CAS  Google Scholar 

  31. Desta Z, Soukhova N, Mahal SK, Flockhart DA (2000) Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 28:789–800

    PubMed CAS  Google Scholar 

  32. Bourrie M, Meunier V, Berger Y, Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321–332

    PubMed CAS  Google Scholar 

  33. Colussi DM, Parisot CY, Lefevre GY (1998) Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor. J Clin Pharmacol 38:727–735

    PubMed CAS  Google Scholar 

  34. Xu C, Goodz S, Sellers EM, Tyndale RF (2002) CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 54:1245–1256

    Article PubMed CAS  Google Scholar 

  35. Sioufi A, Gauducheau N, Pineau V et al (1997) Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 18:779–789

    Article PubMed CAS  Google Scholar 

  36. Liu XD, Xie L, Zhong Y, Li CX (2000) Gender difference in letrozole pharmacokinetics in rats. Acta Pharmacol Sin 21:680–684

    PubMed CAS  Google Scholar 

  37. Ingle JN, Suman VJ, Johnson PA et al (1999) Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 5:1642–1649

    PubMed CAS  Google Scholar 

Download references

Acknowledgments

This study was supported in part by a Pharmacogenetics Research Network Grant (U-01 GM61373), which supports the Consortium on Breast Cancer Pharmacogenomics (COBRA), a Clinical Pharmacology training Grant (T32GM008425) and an RO1 grant (1R01GM078501-01A1) from the National Institute of General Medical Sciences, National Institutes of Health (Bethesda, MD), and by a fellowship award to Dr. Jeong from the Research Institute of Medical Science of Chonnam National University, Gwangju, S. Korea.

Conflict of interest statement

The authors have no conflict of interest.

Author information

Author notes

  1. Seongwook Jeong

    Present address: Department of Anesthesiology, Chonnam University Medical School, Gwangju, South Korea

Authors and Affiliations

  1. Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 1001 West 10th Street, WD Myers Bldg., W7123, Indianapolis, IN, 46202, USA

    Seongwook Jeong, David A. Flockhart & Zeruesenay Desta

  2. Novartis Pharmaceutical Corporation, Florham Park, NJ, USA

    Margaret M. Woo

Authors
  1. Seongwook Jeong

    You can also search for this author inPubMed Google Scholar

  2. Margaret M. Woo

    You can also search for this author inPubMed Google Scholar

  3. David A. Flockhart

    You can also search for this author inPubMed Google Scholar

  4. Zeruesenay Desta

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toZeruesenay Desta.

Rights and permissions

About this article

Cite this article

Jeong, S., Woo, M.M., Flockhart, D.A.et al. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro.Cancer Chemother Pharmacol64, 867–875 (2009). https://doi.org/10.1007/s00280-009-0935-7

Download citation

Keywords

Access this article

Subscribe and save

Springer+ Basic
¥17,985 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Japan)

Instant access to the full article PDF.

Advertisement

[8]ページ先頭
©2009-2025 Movatter.jp